The United States Justice Department has filed a complaint against Regeneron Pharmaceuticals, accusing the company of fraudulent practices related to Medicare reimbursement for its drug, Eylea. The complaint, resulting from an investigation conducted in collaboration with the Office of Inspector General at the Department of Health and Human Services (HHS), alleges that Regeneron manipulated the average sales price reports for Eylea, leading to fraudulent drug pricing reporting. This manipulation is said to have inflated the costs of Eylea to Medicare, thereby enhancing Regeneron's revenues over many years. The case has been brought under the False Claims Act, highlighting the serious nature of the allegations against Regeneron.